Model protocol to study pharmacogenomics in inflammatory diseases

Human rheumatoid arthritis

Mukundan Attur, Clifton Bingham, Mandar Dave, Steven B. Abramson, Ashok R. Amin

Research output: Contribution to journalArticle

Abstract

Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease- modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalDrug Development Research
Volume49
Issue number1
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Pharmacogenetics
Rheumatoid Arthritis
Pharmaceutical Preparations
Molecular Medicine
Poisons
Microarrays
Clinical Protocols
Drug Resistance
Proteomics
Medicine
Arthritis
Clinical Trials
Technology
Gene Expression
Pharmacogenomic Testing
Proteins

Keywords

  • Clinical trials
  • DMARD
  • Genomics
  • NSAIDs
  • Pharmacogenomics
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Model protocol to study pharmacogenomics in inflammatory diseases : Human rheumatoid arthritis. / Attur, Mukundan; Bingham, Clifton; Dave, Mandar; Abramson, Steven B.; Amin, Ashok R.

In: Drug Development Research, Vol. 49, No. 1, 2000, p. 29-33.

Research output: Contribution to journalArticle

Attur, Mukundan ; Bingham, Clifton ; Dave, Mandar ; Abramson, Steven B. ; Amin, Ashok R. / Model protocol to study pharmacogenomics in inflammatory diseases : Human rheumatoid arthritis. In: Drug Development Research. 2000 ; Vol. 49, No. 1. pp. 29-33.
@article{334a6e2bd6004af5a68f9167af466cb4,
title = "Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis",
abstract = "Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease- modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc.",
keywords = "Clinical trials, DMARD, Genomics, NSAIDs, Pharmacogenomics, Rheumatoid arthritis",
author = "Mukundan Attur and Clifton Bingham and Mandar Dave and Abramson, {Steven B.} and Amin, {Ashok R.}",
year = "2000",
doi = "10.1002/(SICI)1098-2299(200001)49:1<29::AID-DDR5>3.0.CO;2-L",
language = "English (US)",
volume = "49",
pages = "29--33",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Model protocol to study pharmacogenomics in inflammatory diseases

T2 - Human rheumatoid arthritis

AU - Attur, Mukundan

AU - Bingham, Clifton

AU - Dave, Mandar

AU - Abramson, Steven B.

AU - Amin, Ashok R.

PY - 2000

Y1 - 2000

N2 - Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease- modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc.

AB - Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease- modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. (C) 2000 Wiley-Liss, Inc.

KW - Clinical trials

KW - DMARD

KW - Genomics

KW - NSAIDs

KW - Pharmacogenomics

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0034073771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034073771&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2299(200001)49:1<29::AID-DDR5>3.0.CO;2-L

DO - 10.1002/(SICI)1098-2299(200001)49:1<29::AID-DDR5>3.0.CO;2-L

M3 - Article

VL - 49

SP - 29

EP - 33

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 1

ER -